Journal article

Safety, efficacy, and biomarker findings of PBT2 in targeting A beta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Lars Lannfelt, Kaj Blennow, Henrik Zetterberg, Stellan Batsman, David Ames, John Hrrison, Colin L Masters, Steve Targum, Ashley I Bush, Ross Murdoch, Janet Wilson, Craig W Ritchie

Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2008